| Manufacturer |
Novo Nordisk |
Eli Lilly and Company |
| Pricing |
Manufacturer self-pay offers:
- Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
- Standard Injection Offers: Approximately $349–$499/month, depending on dose and eligibility.
- Oral Formulation: Self-pay offers starting at $149/month.
Retail prices may be higher. |
Manufacturer self-pay options:
- Starting Price: $299/month for the 2.5 mg starting dose.
- Higher Doses: Monthly costs increase depending on prescribed dosage.
- Eligibility: Pricing depends on delivery device and manufacturer program requirements.
Retail prices may be higher. |
| Insurance Coverage |
- Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
- Medicare Part D: Coverage may be available for medically eligible beneficiaries.
- Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
|
- Commercial Insurance: Some plans cover Zepbound for eligible patients with obesity or other approved indications.
- Prior Authorization: Medical eligibility and documentation may be required.
- Medicare: Coverage depends on the approved indication, applicable program rules, and individual plan.
|
| Main Purpose |
Improve blood sugar control in adults with type 2 diabetes. |
Long-term weight loss and weight maintenance in eligible adults with obesity or overweight. |
| Secondary Purposes |
- Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
- Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
|
- Sleep Apnea: Treat moderate to severe obstructive sleep apnea in adults with obesity.
- Metabolic Health: May improve blood sugar regulation and other metabolic measures.
|
| Active Ingredient |
Semaglutide, a GLP-1 receptor agonist. |
Tirzepatide, a dual GIP and GLP-1 receptor agonist. |
| Benefits |
- Blood Sugar Control: Lowers blood glucose and HbA1c.
- Weight Management: May promote weight loss.
- Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
- Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
|
- Weight Loss: Produces substantial average weight reduction in eligible adults.
- Appetite Regulation: Reduces hunger and food intake.
- Metabolic Health: May improve weight-related metabolic measures.
- Sleep Apnea: Reduces obstructive sleep apnea severity in eligible adults with obesity.
|
| Potential Health Risks |
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Eye Complications: Possible worsening of diabetic retinopathy.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
- Pancreatitis: Potential acute pancreatic inflammation.
- Gallbladder Problems: Including gallstones and gallbladder inflammation.
- Kidney Injury: Possible dehydration-related acute kidney injury.
- Gastrointestinal Reactions: Potentially severe digestive symptoms.
- Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
|
| Weight Loss Potential |
Can produce clinically meaningful weight loss, but results depend on dosage, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss. |
Approximately 15%–21% average body-weight reduction in major trials involving adults without diabetes, depending on dosage and study conditions. Individual results vary. |
| Administration |
- Injection: Subcutaneous injection once weekly.
- Oral Tablet: Once-daily oral formulation with specific administration instructions.
|
- Injection: Subcutaneous injection once weekly.
- Injection Sites: Abdomen, thigh, or upper arm.
- Available Forms: Different injection devices and vial presentations.
|
| Dosing Considerations |
- Starting Injection Dose: Typically 0.25 mg weekly.
- Dose Escalation: Gradual increases based on treatment response and tolerability.
- Oral Dosing: Follows a separate daily dosing schedule.
|
- Starting Dose: Typically 2.5 mg weekly.
- Dose Escalation: Gradual increases according to response and tolerability.
- Maintenance Dose: Selected according to treatment indication and individual response.
|
| Who May Benefit Most? |
Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications. |
Adults with obesity or qualifying overweight who need long-term weight management, including eligible patients with obesity-related obstructive sleep apnea. |
| How Fast Does It Work? |
- Blood Sugar: Improvements may begin within the first weeks.
- HbA1c: Reductions are generally assessed over approximately 3 months.
- Weight Loss: Typically develops gradually over several months.
|
- Appetite: Changes may begin within the first several weeks.
- Initial Weight Loss: May become noticeable within several weeks.
- Substantial Weight Loss: Generally develops over several months, with major trials assessing outcomes at approximately 72 weeks.
|
| Potential Side Effects |
- Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
- Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
|
- Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
- Other Effects: Fatigue and injection-site reactions.
- Timing: Gastrointestinal symptoms frequently occur during dose escalation.
|